Alphagan, Mirvaso(brimonidine)
Alphagan P, Brimonidine, Combigan, Lumify, Mirvaso, Qoliana, Simbrinza (brimonidine) is a small molecule pharmaceutical. Brimonidine was first approved as Alphagan on 1996-09-06. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension, open-angle glaucoma, and skin diseases. The pharmaceutical is active against alpha-2B adrenergic receptor, alpha-2C adrenergic receptor, and alpha-2A adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Alphagan p, Lumify, Mirvaso, Qoliana (generic drugs available since 2003-05-28, discontinued: Alphagan)
CombinationsCombigan, Simbrinza (generic drugs available since 2003-05-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brimonidine tartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALPHAGAN P | AbbVie | N-021262 RX | 2001-03-16 | 1 products, RLD, RS |
| ALPHAGAN P | AbbVie | N-021770 RX | 2005-08-19 | 1 products, RLD, RS |
| LUMIFY | Bausch Health Companies | N-208144 OTC | 2017-12-22 | 1 products, RLD, RS |
| MIRVASO | Galderma | N-204708 RX | 2013-08-23 | 1 products, RLD, RS |
| QOLIANA | Sandoz | N-021764 RX | 2006-05-22 | 1 products, RLD, RS |
Show 2 discontinued
Brimonidine tartrate
+
Brinzolamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SIMBRINZA | Alcon Research | N-204251 RX | 2013-04-19 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alphagan p | New Drug Application | 2013-10-23 |
| brim-dor pf | unapproved drug other | 2018-05-08 |
| brimonidine | ANDA | 2023-02-03 |
| brimonidine tartrate | New Drug Application | 2024-01-11 |
| brimonidine tartrate 0.25% / ivermectin 1% / metronidazole 1% / niacinamide 4% | unapproved drug other | 2019-05-15 |
| brimonidine tartrate 0.25% / potassium azeloyl diglycinate 8% | unapproved drug other | 2019-05-15 |
| brimonidine tartrate and timolol maleate | ANDA | 2023-10-31 |
| brimonidine tartrate ophthalmic solution, 0.15% | ANDA | 2023-07-06 |
| brimonidine tartrate/timolol maleate | ANDA | 2023-11-03 |
| brimonidine tartrate/timolol maleate ophthalmic solution | ANDA | 2023-12-01 |
Show 6 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Brimonidine Tartrate, Mirvaso, Galderma Labs Lp | |||
| 8053427 | 2031-06-13 | DP | U-1428 |
| 8163725 | 2031-06-13 | DP | |
| 10201517 | 2031-06-13 | DP | |
| 8513247 | 2031-03-25 | DP | U-1428 |
| 8513249 | 2031-03-25 | DP | U-1428 |
| 9861631 | 2031-03-25 | U-1428 | |
| 9861632 | 2031-03-25 | U-1428 | |
| 7439241 | 2025-08-25 | U-1428 | |
| 8231885 | 2025-05-24 | DP | |
| 8410102 | 2025-05-24 | U-1428 | |
| 8426410 | 2025-05-24 | U-1428 | |
| 8859551 | 2024-05-25 | U-1428 | |
| Brimonidine Tartrate / Brinzolamide, Simbrinza, Alcon Labs Inc | |||
| 9044484 | 2030-10-30 | DP | |
| 9421265 | 2030-06-17 | DP | |
| Brimonidine Tartrate, Lumify, Bausch And Lomb Inc | |||
| 8293742 | 2030-07-14 | U-2222 | |
| 9259425 | 2030-07-14 | U-2222 | |
| 11596600 | 2029-07-27 | U-2222 | |
| 11833245 | 2029-07-27 | U-2222 | |
| Brimonidine Tartrate, Qoliana, Sandoz | |||
| 7265117 | 2025-08-19 | DP | |
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX21: Brimonidine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EA: Sympathomimetics in glaucoma therapy
— S01EA05: Brimonidine
— S01G: Decongestants and antiallergics
— S01GA: Sympathomimetics used as decongestants
— S01GA07: Brimonidine
HCPCS
No data
Clinical
Clinical Trials
194 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 2 | 6 | 21 | 21 | 9 | 59 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 2 | 2 | 7 | 24 | 10 | 45 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 6 | 13 | 18 | 4 | 41 |
| Rosacea | D012393 | — | L71 | — | — | 4 | 4 | 3 | 11 |
| Intraocular pressure | D007429 | — | — | 2 | — | — | 1 | 5 | 8 |
| Low tension glaucoma | D057066 | EFO_1001022 | H40.12 | — | — | — | 3 | — | 3 |
| Ocular physiological phenomena | D009799 | — | — | — | — | — | 1 | 2 | 3 |
| Angle-closure glaucoma | D015812 | — | — | — | — | — | 1 | 1 | 2 |
| Capsule opacification | D058442 | — | H26.4 | — | — | — | 1 | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Presbyopia | D011305 | — | H52.4 | 6 | 3 | 6 | — | — | 15 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 2 | 2 | 4 | — | 1 | 9 |
| Miosis | D015877 | HP_0000616 | H57.03 | — | 1 | 4 | — | — | 5 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | 1 | 2 | — | 1 | 4 |
| Refractive errors | D012030 | EFO_0003908 | H52.7 | 1 | 2 | 1 | — | — | 4 |
| Erythema | D004890 | HP_0010783 | L53.9 | — | — | 2 | — | 1 | 3 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | 3 | 1 | — | — | 3 |
| Dry eye syndromes | D015352 | — | H04.12 | 1 | 2 | 1 | — | — | 3 |
| Hyperemia | D006940 | EFO_0003822 | H34.82 | 1 | — | 2 | — | — | 3 |
| Exfoliation syndrome | D017889 | EFO_0004235 | — | — | — | 1 | — | 1 | 2 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 4 | — | — | — | 4 |
| Healthy volunteers/patients | — | — | — | — | 1 | — | — | 1 | 2 |
| Macular edema | D008269 | — | — | — | 1 | — | — | — | 1 |
| Hand-foot syndrome | D060831 | EFO_1001893 | — | — | 1 | — | — | — | 1 |
| Meibomian gland dysfunction | D000080343 | — | H02.88 | 1 | 1 | — | — | — | 1 |
| Geographic atrophy | D057092 | — | — | — | 1 | — | — | — | 1 |
| Retinitis pigmentosa | D012174 | HP_0000580 | H35.52 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pseudophakia | D019591 | — | — | 1 | — | — | — | — | 1 |
| Flushing | D005483 | — | R23.2 | 1 | — | — | — | — | 1 |
| Alcohol-related disorders | D019973 | — | F10 | 1 | — | — | — | — | 1 |
| Sjogren-larsson syndrome | D016111 | Orphanet_816 | E71.3 | 1 | — | — | — | — | 1 |
| Vitrectomy | D014821 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | HP_0000518 | H26.9 | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Pterygium | D011625 | — | H11.0 | — | — | — | — | 1 | 1 |
| Coronavirus | D017934 | — | — | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Ventricular dysfunction | D018754 | — | — | — | — | — | — | 1 | 1 |
| Atrial heart septal defects | D006344 | Orphanet_1478 | Q21.1 | — | — | — | — | 1 | 1 |
| Pericardial effusion | D010490 | HP_0001698 | I31.39 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Hydronephrosis | D006869 | EFO_0005562 | N13.30 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Brimonidine |
| INN | brimonidine |
| Description | Brimonidine is a quinoxaline derivative, a secondary amine and a member of imidazoles. It has a role as an adrenergic agonist, an antihypertensive agent and an alpha-adrenergic agonist. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Brc1c(NC2=NCCN2)ccc2nccnc12 |
Identifiers
| PDB | — |
| CAS-ID | 59803-98-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL844 |
| ChEBI ID | 3175 |
| PubChem CID | 2435 |
| DrugBank | DB00484 |
| UNII ID | E6GNX3HHTE (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA2B
ADRA2B
ADRA2C
ADRA2C
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Brimonidine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Brimonidine
+
Timolol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,079 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,969 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use